Effector Therapeutics Inc Asset Resilience Ratio
Effector Therapeutics Inc asset resilience ratio. Effector Therapeutics Inc (EFTR) has an Asset Resilience Ratio of 36.40% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Effector Therapeutics Inc (EFTR) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Effector Therapeutics Inc (2021–2023)
Asset resilience ratio of Effector Therapeutics Inc from 2021 to 2023. This chart shows how Effector Therapeutics Inc's Asset Resilience Ratio has changed over time. Read EFTR liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Effector Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see EFTR asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $9.88 Million | 36.4% |
| Total Liquid Assets | $9.88 Million | 36.40% |
Asset Resilience Insights
- Very High Liquidity: Effector Therapeutics Inc maintains exceptional liquid asset reserves at 36.40% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Effector Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Effector Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Effector Therapeutics Inc Asset Resilience Ratio by Year (2021–2023)
Effector Therapeutics Inc asset resilience ratio by year from 2021 to 2023. The table below shows the annual Asset Resilience Ratio data for Effector Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 17.01% | $3.50 Million | $20.54 Million | -43.52pp |
| 2022-12-31 | 60.54% | $17.60 Million | $29.08 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $54.06 Million | -- |
About Effector Therapeutics Inc
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and a… Read more